Researchers from the University of California, San Francisco, found that cells with oncogenic KRAS mutations have increased levels of ferrous iron (Fe2+) that could, potentially, be used to “turn on” drugs that target cancer cells. The researchers’ findings could give new life to effective cancer drugs that fell out of favor because of the harm they cause to healthy cells. Adding an iron-activated trigger can make the difference.